A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

Most anticancer drugs entering clinical trials fail to achieve approval from the US FDA. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its appl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sivanand, Sharanya, Peña-Llopis, Samuel, Zhao, Hong, Kucejova, Blanka, Spence, Patrick, Pavia-Jimenez, Andrea, Yamasaki, Toshinari, McBride, David J., Gillen, Jessica, Wolff, Nicholas C., Morlock, Lorraine, Lotan, Yair, Raj, Ganesh V., Sagalowsky, Arthur, Margulis, Vitaly, Cadeddu, Jeffrey A., Ross, Mark T., Bentley, David R., Kabbani, Wareef, Xie, Xian-Jin, Kapur, Payal, Williams, Noelle S., Brugarolas, James
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570965/
https://ncbi.nlm.nih.gov/pubmed/22674553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3003643
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados